What is Ikonisys?
Ikonisys SA operates at the intersection of advanced microscopy and oncology, providing a fully-automated diagnostic ecosystem designed to enhance the accuracy of rare cell analysis. The company's flagship Ikoniscope20 platform serves as a cornerstone for its clinical offerings, which have achieved significant regulatory milestones, including FDA clearance and CE certification. By focusing on the detection of Circulating Tumor Cells (CTC), Ikonisys addresses critical unmet needs in liquid biopsy, offering clinicians reliable data to improve patient outcomes. The company's multi-national presence allows it to integrate diverse clinical insights, ensuring its diagnostic tests remain at the forefront of medical innovation.
How much funding has Ikonisys raised?
Ikonisys has raised a total of $56.4M across 10 funding rounds:
Unspecified
$3.8M
Unspecified
$1.4M
Debt
$117K
Debt
$6.3M
Share Placement
$535K
Share Placement
$208K
Other Financing Round
$541K
Unspecified (2010): $3.8M featuring Goldman Sachs and Trevi Health Ventures
Unspecified (2012): $1.4M backed by Trevi Health Ventures and Syneresis s.r.l.
Debt (2021): $117K with participation from PPP
Debt (2022): $6.3M led by Negma Group
Share Placement (2023): $535K supported by The Cambria Group
Share Placement (2024): $208K, investors not publicly disclosed
Other Financing Round (2025): $541K, investors not publicly disclosed
Key Investors in Ikonisys
Trevi Health Ventures
A specialist investment firm providing healthcare-focused alternative asset management with a strong emphasis on medical devices and biopharmaceuticals.
Goldman, Sachs & Co.
A leading global investment banking and securities firm providing comprehensive financial services, including strategic advisory and capital market financing.
New Science Ventures
A venture capital firm focused on early and late-stage companies that utilize novel scientific approaches within the life sciences and information technology sectors.
What's next for Ikonisys?
Looking ahead, the strategic deployment of the $541K will likely focus on accelerating the commercialization of new diagnostic tests and expanding the footprint of the Ikoniscope20 platform. As the company transitions into its next phase of growth, the focus will remain on deepening its intellectual property portfolio and enhancing the sensitivity of its CTC-based liquid biopsy applications. With a history of support from institutional backers such as Trevi Health Ventures, Goldman Sachs, and New Science Ventures, Ikonisys is equipped to sustain its research and development momentum. The firm's ability to secure diverse financing—ranging from debt instruments to share placements—demonstrates a sophisticated approach to capital management that will be essential as it seeks to capture a larger share of the global cancer diagnostics market.
See full Ikonisys company page
